Skip to content
1202
Dr. Anna Kwong
鄺祉彤
qualifications
PhD., MPhil., BSc.
rank
Research Assistant Professor
email
annakwong@cuhk.edu.hk

Specific Research / Sites of Interest

  • Mechanistic investigation of immunotherapy resistance and immune evasion in solid tumors
  • Crosstalk between innate immune cells and the tumor microenvironment in inflammation-associated malignancies, particularly hepatobiliary, pancreatic, and lung cancers
  • Development of combinatorial therapeutic strategies to remodel the immune microenvironment and enhance responsiveness to immune checkpoint blockade

Short Biography

Dr Anna Kwong obtained her undergraduate degree in Biochemistry from the School of Life Sciences at The Chinese University of Hong Kong. She subsequently pursued her MPhil and PhD in Medical Sciences in the Department of Clinical Oncology at CUHK, focusing on tumor immunology and therapeutic modulation of the tumor microenvironment. Dr Kwong continued her postdoctoral training in the same department and was appointed as a Research Assistant Professor in 2025.

 

Dr Kwong applies advanced experimental approaches such as high-parameter flow cytometry, multiplex immunofluorescence staining, three-dimensional cell cultures, and murine tumor models to investigate immune regulatory circuits that govern tumor progression and therapeutic response. She has published her research in leading international journals, including Molecular Therapy, Gut, and the Journal of Hepatology. Her long-term goal is to develop rational immunotherapeutic strategies to overcome immune resistance and improve clinical outcomes in cancer patients.

Most Representative Publications

1. T.T. Kwong, Z.W. Xiong, Y.L. Zhang, H.R. Wu, J.Q Cao, P.P.C. Wong, X.Y. Liu, J. Wang, C.H. Wong, G.M.K. Tse, J.J.Y.Sung, J.Y Zhou, A.S.L. Cheng, S.L. Chan. Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma by Targeting Myeloid IL-8/CXCR2 Signaling. Molecular Therapy. 2025 Feb 5:S1525-0016(25)00092-9.
2. L. L. Chan, T.T. Kwong, J.C.W. Yau, S.L. Chan. Treatment for hepatocellular carcinoma after immunotherapy. Annals of Hepatology. 2025 Feb 2:S1665-2681(25)00007-9.
3. X.L. Long, T.T. Kwong, A.S.L. Cheng, S.L. Chan. Targeting Tumour Endothelial Cells in Liver Cancer: The end of beginning. Journal of Hepatology. 2024 Dec 25:S0168-8278(24)02819-8.
4. T.T. Kwong, H.H. Deng, C.H. Wong, A.W.H. Chan, L.L Chan, S.H.K. Chok, P.N. Cheng, S. Chan. PEG-BCT-100 and Canavanine Synergistically Induce Apoptosis in Arginine Biosynthetic Enzyme-Deficient Pancreatic Cancer. Cancer Research Communications. 2024. 4 (12): 3180–3189.
5. Y.L. Tu, H.R Wu, C.P. Zhong, Z.W. Xiong, J. Wang, S.Y. Chen, P.P.C. Wong, W.Q. Yang, J.H. Lu, S.F. Chen, Z.X. Liang, L.Y. Zhang, Y. Feng, W.W.Y.S. Tou, B.Y. Yin, J.X. Liang, L.Y. Liang, T.T. Kwong, H.H.W. Leung, K.F. To, S. Ma, H.Y. Sun, Q. Xia, J.Y. Zhou, D. Kerr, N.K. Thangue, J.J.Y. Sung, S.L. Chan, A.S.L. Cheng. Epigenetic Activation of STAT1-GSDME Pyroptotic Circuitry Reinforces Immune-checkpoint Targeting for Hepatocellular Carcinoma. Gut. 2024 Nov 1:gutjnl-2024-332281. doi: 10.1136/gutjnl-2024-332281.
6. X.Y. Liu, M. Liu, H.R. Wu, W.S. Tang, W.Q. Yang, T.T.H. Chan, L.Y. Zhang, S.F. Chen, Z.W. Xiong, J.X. Liang, W.W.Y.S Tou, T. Siu, J.Q. Li, J.Q. Cao, C.P. Zhong, H.Y. Sun, T.T. Kwong, H.H.W. Leung, J. Wong, P.B.S Lai, K.F. To, T.X. Xiang, J.J.Y. Sung, S.L. Chan, J.Y. Zhou, A.S.L. Cheng. PPP1R15A-expressing monocytic MDSCs promote immunosuppressive liver microenvironment in fibrosis-associated hepatocellular carcinoma. JHEP Reports. 2024 Jul 6(7):101087.
7. Z.W. Xiong, S.L Chan, J.Y Zhou, J.S.L. Vong, T.T Kwong, X.Z Zeng, J.Q Cao, Y.L Tu, H.R. Wu, Y. Feng, W.Q. Yang, J. Wang, W.S Tang, Z.X Liang, J.H Lu, X.Y Liu, H.H.W. Leung, A.W.H. Chan, K.F To, K.Y.L Yip, Y.M.D Lo, J.J.Y. Sung, A.S.L. Cheng. Targeting PPAR-gamma counteracts tumor adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut. 2023;72:1758-1773.
8. T.T. Kwong, C.H. Wong, J.Y. Zhou, A.S.L. Cheng, J.J.Y. Sung, A.W.H. Chan, S.L. Chan. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade. JHEP Reports. 2020 Dec 20;3(2):100224.